|
1
|
Ouyang W, Kolls JK and Zheng Y: The
biological functions of T helper 17 cell effector cytokines in
inflammation. Immunity. 28:454–467. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Marengo A, Rosso C and Bugianesi E: Liver
cancer: Connections with obesity, fatty liver, and cirrhosis. Annu
Rev Med. 67:103–117. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gomes AL, Teijeiro A, Buren S, Tummala KS,
Yilmaz M, Waisman A, Theurillat JP, Perna C and Djouder N:
Metabolic Inflammation-Associated IL-17A causes Non-alcoholic
steatohepatitis and hepatocellular carcinoma. Cancer Cell.
30:161–175. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
He D, Li H, Yusuf N, Elmets CA, Li J,
Mountz JD and Xu H: IL-17 promotes tumor development through the
induction of tumor promoting microenvironments at tumor sites and
myeloid-derived suppressor cells. J Immunol. 184:2281–2288. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sun C, Kono H, Furuya S, Hara M, Hirayama
K, Akazawa Y, Nakata Y and Fujii H: Interleukin-17A plays a pivotal
role in chemically induced hepatocellular carcinoma in mice. Dig
Dis Sci. 61:474–488. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yang B, Kang H, Fung A, Zhao H, Wang T and
Ma D: The role of interleukin 17 in tumour proliferation,
angiogenesis, and metastasis. Mediators Inflamm. 2014:6237592014.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Grivennikov SI and Karin M: Dangerous
liaisons: STAT3 and NF-kappaB collaboration and crosstalk in
cancer. Cytokine Growth Factor Rev. 21:11–19. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang L, Yi T, Zhang W, Pardoll DM and Yu
H: IL-17 enhances tumor development in carcinogen-induced skin
cancer. Cancer Res. 70:10112–10120. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang B, Rong G, Wei H, Zhang M, Bi J, Ma
L, Xue X, Wei G, Liu X and Fang G: The prevalence of Th17 cells in
patients with gastric cancer. Biochem Biophys Res Commun.
374:533–537. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chen WC, Lai YH, Chen HY, Guo HR, Su IJ
and Chen HH: Interleukin-17-producing cell infiltration in the
breast cancer tumour microenvironment is a poor prognostic factor.
Histopathology. 63:225–233. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xu C, Hao K, Yu L and Zhang X: Serum
interleukin-17 as a diagnostic and prognostic marker for non-small
cell lung cancer. Biomarkers. 19:287–290. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang X, Weng W, Xu W, Wang Y, Yu W, Tang
X, Ma L, Pan Q, Wang J and Sun F: Prognostic significance of
interleukin 17 in cancer: A meta-analysis. Int J Clin Exp Med.
7:3258–3269. 2014.PubMed/NCBI
|
|
13
|
Wu J, Du J, Liu L, Li Q, Rong W, Wang L,
Wang Y, Zang M, Wu Z, Zhang Y and Qu C: Elevated pretherapy serum
IL17 in primary hepatocellular carcinoma patients correlate to
increased risk of early recurrence after curative hepatectomy. PLoS
One. 7:e500352012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang JP, Yan J, Xu J, Pang XH, Chen MS,
Li L, Wu C, Li SP and Zheng L: Increased intratumoral
IL-17-producing cells correlate with poor survival in
hepatocellular carcinoma patients. J Hepatol. 50:980–989. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Numasaki M, Fukushi J, Ono M, Narula SK,
Zavodny PJ, Kudo T, Robbins PD, Tahara H and Lotze MT:
Interleukin-17 promotes angiogenesis and tumor growth. Blood.
101:2620–2627. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pan B, Shen J, Cao J, Zhou Y, Shang L, Jin
S, Cao S, Che D, Liu F and Yu Y: Interleukin-17 promotes
angiogenesis by stimulating VEGF production of cancer cells via the
STAT3/GIV signaling pathway in non-small-cell lung cancer. Sci Rep.
5:160532015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wu X, Yang T, Liu X, Guo JN, Xie T, Ding
Y, Lin M and Yang H: IL-17 promotes tumor angiogenesis through
Stat3 pathway mediated upregulation of VEGF in gastric cancer.
Tumour Biol. 37:5493–5501. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu J, Duan Y, Cheng X, Chen X, Xie W,
Long H, Lin Z and Zhu B: IL-17 is associated with poor prognosis
and promotes angiogenesis via stimulating VEGF production of cancer
cells in colorectal carcinoma. Biochem Biophys Res Commun.
407:348–354. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mihara K, Smit MJ, Krajnc-Franken M,
Gossen J, Rooseboom M and Dokter W: Human CXCR2 (hCXCR2) takes over
functionalities of its murine homolog in hCXCR2 knockin mice. Eur J
Immunol. 35:2573–2582. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Addison CL, Daniel TO, Burdick MD, Liu H,
Ehlert JE, Xue YY, Buechi L, Walz A, Richmond A and Strieter RM:
The CXC chemokine receptor 2, CXCR2, is the putative receptor for
ELR+ CXC chemokine-induced angiogenic activity. J Immunol.
165:5269–5277. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Palacios-Arreola MI, Nava-Castro KE,
Castro JI, Garcia-Zepeda E, Carrero JC and Morales-Montor J: The
role of chemokines in breast cancer pathology and its possible use
as therapeutic targets. J Immunol Res. 2014:8497202014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kitadai Y, Haruma K, Sumii K, Yamamoto S,
Ue T, Yokozaki H, Yasui W, Ohmoto Y, Kajiyama G, Fidler IJ and
Tahara E: Expression of interleukin-8 correlates with vascularity
in human gastric carcinomas. Am J Pathol. 152:93–100.
1998.PubMed/NCBI
|
|
23
|
Mestas J, Burdick MD, Reckamp K, Pantuck
A, Figlin RA and Strieter RM: The role of CXCR2/CXCR2 ligand
biological axis in renal cell carcinoma. J Immunol. 175:5351–5357.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhu B, Lin N, Zhang M, Zhu Y, Cheng H,
Chen S, Ling Y, Pan W and Xu R: Activated hepatic stellate cells
promote angiogenesis via interleukin-8 in hepatocellular carcinoma.
J Transl Med. 13:3652015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Numasaki M, Watanabe M, Suzuki T,
Takahashi H, Nakamura A, McAllister F, Hishinuma T, Goto J, Lotze
MT, Kolls JK and Sasaki H: IL-17 enhances the net angiogenic
activity and in vivo growth of human non-small cell lung cancer in
SCID mice through promoting CXCR-2-dependent angiogenesis. J
Immunol. 175:6177–6189. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhou Y, Wu PW, Yuan XW, Li J and Shi XL:
Interleukin-17A inhibits cell autophagy under starvation and
promotes cell migration via TAB2/TAB3-p38 mitogen-activated protein
kinase pathways in hepatocellular carcinoma. Eur Rev Med Pharmacol
Sci. 20:250–263. 2016.PubMed/NCBI
|
|
27
|
Li J, Lau GK, Chen L, Dong SS, Lan HY,
Huang XR, Li Y, Luk JM, Yuan YF and Guan XY: Interleukin 17A
promotes hepatocellular carcinoma metastasis via NF-κB induced
matrix metalloproteinases 2 and 9 expression. PLoS One.
6:e218162011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Knowles BB, Howe CC and Aden DP: Human
hepatocellular carcinoma cell lines secrete the major plasma
proteins and hepatitis B surface antigen. Science. 209:497–499.
1980. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lopez-Terrada D, Cheung SW, Finegold MJ
and Knowles BB: Hep G2 is a hepatoblastoma-derived cell line. Hum
Pathol. 40:1512–1515. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sumpter R Jr, Loo YM, Foy E, Li K,
Yoneyama M, Fujita T, Lemon SM and Gale M Jr: Regulating
intracellular antiviral defense and permissiveness to hepatitis C
virus RNA replication through a cellular RNA helicase, RIG-I. J
Virol. 79:2689–2699. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Guide for the care and use of Laboratory
Animals. Eighth editor; Washington, D.C.: 2011
|
|
33
|
Huang J, Zhang X, Tang Q, Zhang F, Li Y,
Feng Z and Zhu J: Prognostic significance and potential therapeutic
target of VEGFR2 in hepatocellular carcinoma. J Clin Pathol.
64:343–348. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liao R, Sun J, Wu H, Yi Y, Wang JX, He HW,
Cai XY, Zhou J, Cheng YF, Fan J and Qiu SJ: High expression of
IL-17 and IL-17RE associate with poor prognosis of hepatocellular
carcinoma. J Exp Clin Cancer Res. 32:32013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tartour E, Fossiez F, Joyeux I, Galinha A,
Gey A, Claret E, Sastre-Garau X, Couturier J, Mosseri V, Vives V,
et al: Interleukin 17, a T-cell-derived cytokine, promotes
tumorigenicity of human cervical tumors in nude mice. Cancer Res.
59:3698–3704. 1999.PubMed/NCBI
|
|
36
|
Hu J, Ye H, Zhang D, Liu W, Li M, Mao Y
and Lu Y: U87MG glioma cells overexpressing IL-17 acclerate
early-stage growth in vivo and cause a higher level of CD31 mRNA
expression in tumor tissues. Oncol Lett. 6:993–999. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Nomiyama H, Osada N and Yoshie O:
Systematic classification of vertebrate chemokines based on
conserved synteny and evolutionary history. Genes Cells. 18:1–16.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Singh S, Varney M and Singh RK: Host
CXCR2-dependent regulation of melanoma growth, angiogenesis, and
experimental lung metastasis. Cancer Res. 69:411–415. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Sun W and Cabrera R: Systemic treatment of
patients with advanced, unresectable hepatocellular carcinoma:
Emergence of therapies. J Gastrointest Cancer. 49:107–115. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Raoul JL, Gilabert M, Adhoute X and
Edeline J: An in-depth review of chemical angiogenesis inhibitors
for treating hepatocellular carcinoma. Expert Opin Pharmacother.
18:1467–1476. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Chung AS, Wu X, Zhuang G, Ngu H, Kasman I,
Zhang J, Vernes JM, Jiang Z, Meng YG, Peale FV, et al: An
interleukin-17-mediated paracrine network promotes tumor resistance
to anti-angiogenic therapy. Nat Med. 19:1114–1123. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Keane MP, Belperio JA, Xue YY, Burdick MD
and Strieter RM: Depletion of CXCR2 inhibits tumor growth and
angiogenesis in a murine model of lung cancer. J Immunol.
172:2853–2860. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Devapatla B, Sharma A and Woo S: CXCR2
Inhibition combined with sorafenib improved antitumor and
antiangiogenic response in preclinical models of ovarian Cancer.
PLoS One. 10:e01392372015. View Article : Google Scholar : PubMed/NCBI
|
